Please use this identifier to cite or link to this item:
Título : Melatonin and human cardiovascular disease
Autor : Pandi Perumal, Seithikurippu R. 
BaHammam, Ahmed S. 
Ojike, Nwakile I. 
Akinseye, Oluwaseun 
Kendzerska, Tetyana 
Buttoo, Kenneth 
Dhandapany, Perundurai S. 
Brown, Gregory M. 
Cardinali, Daniel Pedro 
Fecha de publicación : 2017
Editorial : SAGE Publications
Cita : Pandi-Perumal, S. R., et al. Melatonin and human cardiovascular disease [en línea]. Preprint del documento publicado en Journal of Cardiovascular Pharmacology and Therapeutics. 2017, 22 (2). doi: 10.1177/1074248416660622. Disponible en:
Resumen : Abstract: The possible therapeutic role of melatonin in the pathophysiology of coronary artery disorder (CAD) is increasingly being recognized. In humans, exogenous melatonin has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation and reduce serum catecholamine levels. Low circulating levels of melatonin are reported in individuals with CAD, arterial hypertension and congestive heart failure. This review assesses current literature on the cardiovascular effects of melatonin in humans. It can be concluded that melatonin deserves to be considered in clinical trials evaluating novel therapeutic interventions for cardiovascular disorders.
ISSN : 1940-4034 (en línea)
Disciplina: MEDICINA
Derechos: Acceso Abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
melatonin-human-cardiovascular-disease.pdf887,4 kBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Aug 11, 2022


checked on Aug 11, 2022

Google ScholarTM


This item is licensed under a Creative Commons License Creative Commons